drugset
drugset / Trial / NCT04483791

DynamX Bioadaptor Hong Kong Registry

NCT04483791 ↗

Phase 4 Completed 50 enrolled Elixir Medical Corporation
NaSingle-groupOpen-labelOther

Summary

Prospective, non-randomized, multicenter registry

Timeline

Start
2020-09-30
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background Novolimus Unknown — —

Indications

coronary artery disorder